Azitra, Inc. (AZTR)

Market Cap	5.70M
Revenue (ttm)	97,500
Net Income (ttm)	-9.03M
Shares Out	15.82M
EPS (ttm)	-4.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,237,870
Open	0.400
Previous Close	0.409
Day's Range	0.360 - 0.400
52-Week Range	0.233 - 12.000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 14, 2025

About AZTR

Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2023
• Employees: 10
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: AZTR
• Website: https://azitrainc.com

Financial Performance

In 2023, Azitra's revenue was $686,000, an increase of 141.55% compared to the previous year's $284,000. Losses were -$12.64 million, -6.02% less than in 2022.